Private Third-Party Audits Could Enhance FDA’s Manufacturing Risk Analysis
This article was originally published in The Tan Sheet
Executive Summary
Private and third-party audits could direct FDA to problematic facilities while easing some inspection burden on firms that already comply, but not replace FDA’s typical inspection duties.
You may also be interested in...
Collaboration On Foreign Inspections Helps FDA Improve Resource Allocations
FDA better allocated resources for foreign inspections based on information European and Australian authorities shared in a two-year pilot program, including conducting good manufacturing practices inspections that met the needs of multiple agencies.
Collaboration On Foreign Inspections Helps FDA Improve Resource Allocations
FDA better allocated resources for foreign inspections based on information European and Australian authorities shared in a two-year pilot program, including conducting good manufacturing practices inspections that met the needs of multiple agencies.
Collaboration On Foreign Inspections Helps FDA Improve Resource Allocations
FDA better allocated resources for foreign inspections based on information European and Australian authorities shared in a two-year pilot program, including conducting good manufacturing practices inspections that met the needs of multiple agencies.